Phase 2 Alzheimer's Disease Trial, Recruiting NCT07457125 Sponsor: Xuanwu Hospital, Beijing Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07457125
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 50 years old or older, of any gender.
  • You have been clinically diagnosed with Alzheimer's disease at a mild to moderate stage.
  • You have had a spinal fluid test, a brain amyloid PET scan, or a specific blood test (p-tau217) within the past 3 years that supports an Alzheimer's diagnosis.
  • You have had a brain MRI or CT scan within the past 6 months showing results consistent with mild to moderate Alzheimer's and no other major brain conditions (or you are able to get one before starting treatment).
  • You scored between 10 and 24 (inclusive) on a standard memory and thinking test called the MMSE.
  • You have a score of 4 or below on a test that checks for stroke-related factors (confirm with trial site).
  • You have a reliable caregiver who can read and understand study documents, communicate with the study team, and spends at least 2 hours with you on at least 3 days per week.
  • If you are a woman who could become pregnant, you must use effective birth control throughout the study.
  • You have been taking your current Alzheimer's medications (such as donepezil, memantine, or similar) at the same dose for at least 60 days before joining, and you agree to keep the same dose throughout the study.
  • You (or your legal guardian) are willing and able to sign a consent form and follow the study schedule.

Who may not be able to join:

  • You have had a known allergic reaction to the study drug or similar drugs, or you have a history of severe allergies in general.
  • You have previously received umbilical cord stem cell therapy.
  • Your blood test results show problems with white blood cell counts, platelet counts, kidney function, or liver function outside of acceptable ranges (confirm with trial site).
  • You cannot have an MRI scan due to having a pacemaker, metal implants, electronic devices in your body, or certain other medical devices (a full list should be confirmed with the trial site).
  • You have another brain or neurological condition, such as Parkinson's disease, vascular dementia, epilepsy, multiple sclerosis, Huntington's disease, hydrocephalus, or a history of significant head injury.
  • You have had a serious infection anywhere in your body within the 3 months before screening.
  • You have tested positive for Hepatitis B, Hepatitis C, syphilis, or HIV.
  • You have a history of alcohol or drug misuse, or a psychiatric illness, within the past 10 years.
  • You have a history of cancer (malignant tumors).
  • You have poorly controlled heart, liver, kidney, lung, hormone, or other major organ conditions.
  • You have severe difficulty with speech, hearing, or vision, or other conditions that would make it impossible to complete memory and thinking tests.
  • You have any serious illness where life expectancy is less than 12 months.
  • You are currently pregnant, breastfeeding, or have a positive pregnancy test before the study starts.
  • You are currently taking part in another clinical trial that could affect the results of this study.
  • The study doctor feels there is any other reason participation would not be safe or appropriate for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Junwei Hao, MD; PhD, Xuanwu Hospital, Beijing

Phone: 010 8319 8277

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xuanwu Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
30 May 2026
Est. completion
30 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of serious adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov